KALA BIO
Development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles.
Market cap
$29.0m
Enterprise value
$19m
Share price
$4.76 KALA
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $10.8m | Private Placement VC | |
| Total Funding | 000k | ||
Vivo Capital(exited)
Polaris Partners(exited)
Longitude Capital(exited)
Lux Capital(exited)
Wellington Management(exited)
RA Capital Management(exited)
Abbvie Biotech Ventures(exited)
Crown Venture Fund(exited)
Third Rock Ventures(exited)
Ysios Capital(exited)
Lighthouse Capital Partners(exited)
Oxford Finance(exited)
Athyrium Capital Management(exited)
OrbiMed(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 5 % | 77 % | (65 %) | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1505 %) | (952 %) | (2097 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1640 %) | (1269 %) | (1152 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 288 % | 102 % | 454 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.